Faculty Bibliography

Background and Aims: In this systematic review and individual patient data meta-analysis we aim to explore the association between blood pressure (BP) levels after endovascular thrombectomy (EVT) and the clinical outcomes of acute ischemic stroke (AIS) patients with large vessel occlusion (LVO).
Method(s): A study was eligible if it enrolled AIS patients older than 18 years, with an LVO treated with either successful or unsuccessful EVT, and provided either individual or mean 24-hour systolic BP values after the end of the EVT procedure. Individual patient data from all studies were analyzed using a generalized linear mixed-effects model.
Result(s): A total of 5874 patients (mean age: 69+/-14 years, 50% women, median NIHSS on admission:16) from 7 published studies were included. Increasing mean systolic BP levels per 10 mm Hg during the first 24 hours after the end of the EVTwere associated with a lower odds of functional improvement (unadjusted common OR=0.82, 95%CI:0.80-0.85; adjusted common OR=0.88, 95%CI:0.84-0.93) and modified Ranking Scale score<=2 (unadjusted OR=0.82, 95%CI:0.79-0.85; adjusted OR=0.87, 95%CI:0.82-0.93), and a higher odds of all-cause mortality (unadjusted OR=1.18, 95%CI:1.13-1.24; adjusted OR=1.15, 95%CI:1.06-1.23) at 3 months. Higher 24-hour mean systolic BP levels were also associated with an increased likelihood of early neurological deterioration (unadjusted OR=1.14, 95%CI:1.07-1.21; adjusted OR=1.14, 95%CI:1.03-1.24) and a higher odds of symptomatic intracranial hemorrhage (unadjusted OR=1.20, 95%CI:1.09-1.29; adjusted OR=1.20, 95% CI:1.03-1.38) after EVT.
Conclusion(s): Increased mean systolic BP levels in the first 24 hours after EVT are independently associated with a higher odds of symptomatic intracranial hemorrhage, early neurological deterioration, threemonth mortality, and worse three-month functional outcomes

Several COVID-19 vaccines have recently been approved for emergency use according to governmental immunization programs. The arrival of these vaccines has created hope for people with Parkinson's disease (PD), as this can help to mitigate their risk of becoming infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can lead to serious, life-threatening disease, at least among those with more advanced PD. However, both persons with PD and physicians looking after these individuals have expressed concerns about the vaccine's efficacy and safety in the specific context of PD and its symptomatic treatment. Here, we discuss our perspective on these concerns, based on our interpretation of the literature plus the unfolding experience with widespread vaccination in the population at large. Because the benefits and risks of COVID-19 vaccines do not appear to be different than in the general population, we recommend COVID-19 vaccination with approved vaccines to persons with PD, unless there is a specific contraindication. Some caution seems warranted in very frail and terminally ill elderly persons with PD living in long-term care facilities.

Background: MOG antibody disorder (MOGAD) is associated with diverse clinical phenotypes, including recurrent and bilateral optic neuritis, acute disseminated encephalomyelitis, and longitudinally extensive transverse myelitis with a predilection for the conus medullaris. Spinal nerve root involvement in this disease has rarely been described.
Objective(s): To describe a case of MOG antibody disorder with an unusual radiographic presentation.
Method(s): A case is described and review of the literature was performed.
Result(s): A 53-year-old previously healthy man presented to our hospital with three weeks of numbness and pain involving his right arm, bilateral lower extremities, and perineum. Neurologic exam was notable for decreased sensation in his right hand and left leg, hyperreflexia in bilateral lower extremities, and an extensor plantar response on the left. MRI spine was notable for multifocal short-segment T2 hyperintense lesions consistent with demyelination. There was also contrast enhancement of the cauda equina nerve roots and focal lobular enhancement of the left S1 nerve root. MRI brain showed several small T2 hyperintense brainstem lesions. He was started on pulse dose intravenous steroids while undergoing extensive work-up for inflammatory, infectious, and neoplastic causes. Serology was notable for mildly elevated ACE. CSF showed elevated protein. Given these laboratory and radiographic findings, an inflammatory etiology such as neurosarcoidosis was initially felt to be most likely. CT chest was negative for evidence of pulmonary sarcoid. He demonstrated clinical improvement with steroids and was discharged on a slow taper. MOG antibody in the serum (by cell-based assay) resulted positive at 1:100, suggestive of demyelination in the setting of MOGAD. The patient opted for monthly IV immunoglobulin (IVIG) maintenance therapy and has been clinically stable. Repeat MRI two months later showed stable areas of spinal nerve root enhancement and decrease in some of the cord lesions.
Conclusion(s): Our case demonstrates that MOGAD should be a diagnostic consideration when MRI shows spinal nerve root enhancement in the appropriate clinical context, especially with the additional presence of CNS lesions that are typical of demyelination. MOGAD can manifest clinically and radiographically in both the central and peripheral nervous system

Significant immunological, physical and neurological benefits of breastfeeding in infancy are well-established, but to what extent these gains persist into later childhood remain uncertain. This study examines the association between breastfeeding duration and subsequent domain-specific cognitive performance in a diverse sample of 9-10-year-olds enrolled in the Adolescent Brain Cognitive Development (ABCD) Study®. The analyses included 9,116 children that attended baseline with their biological mother and had complete neurocognitive and breastfeeding data. Principal component analysis was conducted on data from an extensive battery of neurocognitive tests using varimax-rotation to extract a three-component model encompassing General Ability, Executive Functioning, and Memory. Propensity score weighting using generalized boosted modeling was applied to balance the distribution of observed covariates for children breastfed for 0, 1-6, 7-12, and more than 12 months. Propensity score-adjusted linear regression models revealed significant association between breastfeeding duration and performance on neurocognitive tests representing General Ability, but no evidence of a strong association with Executive Function or Memory. Benefits on General Ability ranged from a 0.109 (1-6 months) to 0.301 (>12 months) standardized beta coefficient difference compared to those not breastfed. Results indicate clear cognitive benefits of breastfeeding but that these do not generalize to all measured domains, with implications for public health policy as it pertains to nutrition during infancy.

Background: Cognitive impairment is a common feature of multiple sclerosis (MS). A semi-structured interview, including informant input, can characterize the experience of individuals living with MS and cognitive involvement. Objective: We administered the Cognitive Assessment Interview (CAI), a patient- and informant-based semi-structured interview, to characterize the experience of cognitive impairments in those living with MS. Methods: Trained raters administered the CAI to a sample of MS participants and their informants enrolled for a trial of cognitive remediation. Cognitive impairments on the CAI were characterized and compared to those captured by neuropsychological and self-report measures. Results: A total of n = 109 MS participants (mean age = 50.3 ± 12.2) and their available informants (n = 71) were interviewed. Participants reported experiencing processing speed (90/106, 85%), working memory (87/109, 80%), and learning and memory (79/109, 72%) problems most commonly. CAI-based ratings were moderately correlated with a self-report measure (Multiple Sclerosis Neuropsychological Screening Questionnaire, r_s = 0.52, p < 0.001) and only mildly correlated with objective neuropsychological measures specific to executive functions (r

Background: Modern, highly efficient hemodialysis (HD) results in rapid decline of blood urea. Urea gradients across the blood-brain barrier (BBB) can drive water movements. A positive urea gradient, i.e. brain urea to plasma urea, can result in brain swelling and impair brain function. We explored the dialytic changes of urea in blood and cerebrospinal fluid (CSF) to better understand intradialytic osmotic gradients across the BBB and provide insights that support the development of brain-protective HD.
Method(s): Two HD patients (39 and 26 years old) with ventriculo-peritoneal (VP) shunts were enrolled into this one-week IRB-approved study with a Monday/Wednesday/ Friday dialysis schedule. CSF was collected via VP shunt tap 2 hrs before and 2 hrs after HD (Wednesday and Friday), and Tuesday and Thursday. Plasma samples were collected concurrently with CSF and during HD. In addition, the patients underwent test of executive function (Trail Making Test Part B; TMT B) and global cognitive function (Montreal Cognitive Assessment; MoCA) on Monday.
Result(s): Urea was removed efficiently from patients' blood by HD. While patient A showed a small post-HD plasma-to-CSF urea gradient, it was highly positive (~ 60 mg/dL) in patient B (Fig. 1). TMT B and MoCA score were normal for patient A but not patient B (TMT B 415 sec; TMT B error count: 2; MoCA score: 11).
Conclusion(s): Our patients showed very different post-HD plasma-to-CSF gradients. Theoretically, the positive gradient in patient B would favor intradialytic brain swelling. Patient B showed impaired neurological testing results which are not related to patient's pre-existing neurological conditions. We can only speculate if and to what extent trans-BBB water movements driven by dialytic urea dynamics may have impacted the patient's cognitive functions?. We believe that patient-specific levels of osmotic stress need to be considered when developing neuro-protective HD technologies